

Propylene Carbonate as a Solvent for Asymmetric Hydrogenations**

Jerome Bayardon, Jens Holz, Benjamin Schöffner, Vasyl Andrushko, Sergej Verevkin, Angelika Preetz, and Armin Börner*

Dedicated to Professor Rüdiger Selke

The correct choice of solvent is one of the central problems in synthetic chemistry, for in many cases the physical and toxicological properties of a solvent have a pivotal influence on its use on both the laboratory and industrial scale. Multiphase methods with immiscible solvents allow repeated recycling of the catalyst in homogeneous catalysis.^[1] Prominent examples of this ecologically and economically sensible approach include catalyzed reactions in multiphase systems containing water,^[2] fluorinated hydrocarbons,^[3] supercritical CO₂,^[4] and ionic liquids (ILs).^[5]

Up to now organic cyclic carbonates, in particular propylene carbonate (PC), have not played a role as solvents for asymmetric hydrogenations. The few exceptions in homogeneous catalysis include the platinum-catalyzed hydrosilylation of unsaturated fatty acids investigated by Behr et al.^[6] and regioselective, rhodium-catalyzed hydroformylation in PC as solvent.^[7] Reetz et al. were successful in stabilizing palladium colloids with PC.^[8]

Propylene carbonate is a dipolar aprotic solvent that has previously found application mainly in extractions, electrochemistry, cosmetics, and medicine. In addition to its excellent solvation properties, PC has valuable physical properties such as low viscosity, and it is essentially odorless. Like other organic carbonates PC is usually anhydrous, noncorrosive, nontoxic, and biodegradable.^[9] Based on these properties organic carbonates offer a “safe” and environmentally friendly alternative to standard solvents such as CH₂Cl₂ and THF, as well as aromatic and toxic solvents.^[10] Many alkyl carbonates are available commercially.^[11]

In order to investigate the suitability of PC for asymmetric hydrogenations, rhodium-catalyzed asymmetric hydrogenations were initially carried out with a set of common olefins. The commercially available diphosphanes catASium M,^[12] Me-duphos,^[13] binap,^[14] tol-binap,^[15] and josiphos^[16] were used as ligands. The precatalysts were prepared by reaction of the ligands with [Rh(cod)₂]BF₄ in PC in situ (cod = 1,5-cyclooctadiene).

For comparison the hydrogenations were carried out in parallel in MeOH, THF, and CH₂Cl₂. The results for methyl α -acetylaminocinnamate and dimethyl itaconate are listed in Table 1 and Table 2. It is clear from these measurements that PC is ideally suited for asymmetric hydrogenation, since similar or even higher enantioselectivities are achieved with comparable reactivity.^[17]

Table 1: Rhodium-catalyzed asymmetric hydrogenation of methyl α -acetylaminocinnamate with different phosphane ligands.^[a]

Ligand	ee [%] ^[b]			
	PC	MeOH	THF	CH ₂ Cl ₂
catASium M	97	94	99	98
Me-duphos	99	98	97	98
binap	43	14	45	32
tol-binap	50	4	47	35
josiphos	79	77	86	–

[a] Complexes of the type [Rh(cod)₂]BF₄ (L = ligand) were used as catalysts; catASium M = 2,3-bis[(2*R*,5*R*)-2,5-dimethylphospholanyl]maleic acid anhydride, Me-duphos = 1,2-bis[(2*R*,5*R*)-2,5-dimethylphospholanyl]benzene, binap = (*R*)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl, tol-binap = (*R*)-2,2'-bis(di-*p*-tolylphosphanyl)-1,1'-binaphthyl, josiphos = (*R*)-1-[(*S*)-2-diphenylphosphanyl]ferrocenylethylidicyclohexylphosphane. Substrate/cat. 100:1, 7.5 mL solvent, *p*(H₂) = 1 bar (isobar), 25 °C. [b] Determined by GC, 25 m γ -cyclodextrin, lipodex E (Machery und Nagel), silica, 130 °C, complete conversion after 3 h.

Table 2: Rhodium-catalyzed asymmetric hydrogenation of dimethyl itaconate with different phosphane ligands.^[a]

Ligand	ee [%] ^[b]			
	PC	MeOH	THF	CH ₂ Cl ₂
catASium M	95	60	86	98
Me-duphos	97	95	97	80
binap	73	4	19	77
tol-binap	78	0	5	75
josiphos	99	88	92	–


[a] Complexes of the type [Rh(cod)₂]BF₄ (L = ligand) were used as catalysts; substrate/cat. 100:1, 7.5 mL solvent, *p*(H₂) = 1 bar (isobar), 25 °C. [b] Determined by GC, 25 m γ -cyclodextrin, lipodex E (Machery und Nagel), silica, 130 °C, complete conversion after 3 h.

Since PC is not miscible with nonpolar solvents, a two-phase reaction would allow catalyst recycling. The requirement is that the catalyst is soluble in PC and the product is more soluble in the nonpolar solvent than in PC. This is not the case for the amino acid and dicarboxylate in Tables 1 and 2. In contrast, in the hydrogenation of nonfunctionalized

[*] Dr. J. Bayardon, Dr. J. Holz, Dipl.-Chem. B. Schöffner, Dr. V. Andrushko, Priv.-Doz. Dr. S. Verevkin, Dipl.-Chem. A. Preetz, Prof. Dr. A. Börner
Leibniz-Institut für Katalyse e.V.
Universität Rostock
Albert-Einstein-Strasse 29a, 18059 Rostock (Germany)
Fax: (+49) 381-1281-5202
E-mail: armin.boerner@catalysis.de

[**] We thank the Graduiertenkolleg 1213 of the DFG for financial support.

olefins, the alkanes formed are highly soluble in hexane. Iridium complexes with the oxazoline phosphites **3** and **4** as ligands were used as catalysts (Scheme 1);^[18] these ligands are known to be suitable for the hydrogenation of styrene



Scheme 1. Asymmetric hydrogenation of *p*-substituted α -ethylstyrene.

derivatives such as **1a-d** based on the work of Pfaltz et al.^[19] As can be seen from Table 3, similar enantioselectivity values were obtained in PC, although reaction times were significantly greater in PC than in CH₂Cl₂. Most results show the known dependency of enantioselectivity on hydrogen pressure.^[19]

Table 3: Iridium-catalyzed asymmetric hydrogenation of styrene derivatives in PC and CH₂Cl₂.^[a]

Substr.	Solv.	H ₂ [atm]	[Ir(cod)(3)]BARF ₄ <i>t</i> [h] ^[b]	<i>ee</i> [%] ^[c]	[Ir(cod)(4)]BARF ₄ <i>t</i> [h] ^[b]	<i>ee</i> [%] ^[c]
1a	PC	50	4	61 (S)	4	76 (S)
1a	CH ₂ Cl ₂	50	3	64 (S)	3	52 (S)
1a	PC	1	6	46 (S)	4	83 (S)
1a	CH ₂ Cl ₂	1	0.1	78 (S)	0.1	86 (S)
1b	PC	50	4	62 (S)	4	78 (S)
1b	CH ₂ Cl ₂	50	1	73 (S) ^[d]	2	56 (S) ^[d]
1b	PC	1	7	47 (S)	2	85 (S)
1b	CH ₂ Cl ₂	1	0.5	88 (S) ^[d]	0.5	91 (S) ^[d]
1c	PC	50	4	61 (S)	4	74 (S)
1c	CH ₂ Cl ₂	50	1	71 (S) ^[d]	2	58 (S) ^[d]
1c	PC	1	6	54 (S)	2	82 (S)
1c	CH ₂ Cl ₂	1	0.5	90 (S) ^[d]	0.5	94 (S) ^[d]
1d	PC	50	4	30 (S)	4	74 (S)
1d	CH ₂ Cl ₂	50	1	46 (S) ^[d]	2	54 (S) ^[d]
1d	PC	1	7	5 (S)	6	66 (S)
1d	CH ₂ Cl ₂	1	0.5	59 (S) ^[d]	0.5	88 (S) ^[d]


[a] Conditions: 0.4 mmol substrate, 0.004 mmol [Ir(cod)L]BARF₄, 2 or 8 mL solvent (Solv.), 25 °C. [b] Time for complete conversion. [c] Determined by GC or HPLC. [d] Data from Ref. [19].

In Table 4 the results of a detailed study of the hydrogenation of 1-methylene-1,2,3,4-tetrahydronaphthalene (**5**; Scheme 2) at different hydrogen pressures and temperatures are compared with the results obtained in CH₂Cl₂. The chiral product **7** is formed in this reaction as well as the isomerized olefin **6** as an intermediate, which can also be hydrogenated. The hydrogenation of **5** under normal pressure leads to a mixture of **6** and **7** with conversions of 74–100%. The fraction

Table 4: Iridium-catalyzed asymmetric hydrogenation of **5** in PC and CH₂Cl₂.^[a]

Lig.	Solv.	H ₂ [atm]	<i>t</i> [h]	Conv. [%] ^[b]	6/7 ^[b]	<i>ee</i> [%] ^[c]
3	PC	50	4	100	7:93	8.3 (R)
3	CH ₂ Cl ₂	50	3	100	0:100	25.7 (S)
3	PC	1	20	85	62:38	3.5 (R)
3	CH ₂ Cl ₂	1	3	85	50:50	28.6 (S)
4	PC	50	4	100	13:87	81.3 (R)
			8	100	4:96	82.1 (R)
4	PC	85	4	100	5:95	82.1 (R)
4	PC	100	4	100	3:97	82.4 (R)
4	CH ₂ Cl ₂	50	3	100	0:100	16.9 (R)
4	PC	1	20	74	63:37	73.2 (R)
4	CH ₂ Cl ₂	1	3	100	71:29	46.3 (R)

[a] Conditions: 0.4 mmol substrate, 0.004 mmol [Ir(cod)L]BARF₄, 2 or 8 mL LM, 25 °C. [b] Determined by NMR spectroscopy and GC on chiral phase. [c] Determined by GC on chiral phase.




Scheme 2. Asymmetric hydrogenation of 1-methylene-1,2,3,4-tetrahydronaphthalene (**5**).

of the hydrogenation product **7** is usually higher for reactions in CH₂Cl₂ than those in PC.

Only very low enantioselectivities were obtained with the use of [Ir(cod)(**3**)]BARF₄ (BARF₄ = B(C₆H₃(CF₃)₂)₄); the best value in CH₂Cl₂ was about 28.6% *ee*. For the hydrogenation with iridium catalysts with the ligand **4** the results in PC were significantly better than those in CH₂Cl₂ (increase by about 60% *ee*). Further improvement to 82.4% *ee* was obtained with an increase in pressure.

To explain these differences, the isomerization of the external olefin **5** to the internal olefin **6** was investigated initially in the presence of the iridium catalyst but without hydrogen atmosphere (Scheme 3). DFT calculations confirm that **6** is significantly more stable than **5** with its exocyclic double bond.^[20] NMR spectroscopic investigations show that the isomerization proceeds more slowly in PC than in CH₂Cl₂.^[21]



Scheme 3. Studies on the isomerization and hydrogenation of olefins.

By use of the same catalyst, products with opposite configurations are obtained in the hydrogenation of **5** and **6**. The exocyclic olefin is almost exclusively stereoselectively hydrogenated in PC. In contrast, the parallel hydrogenation of **5** and **6** in CH_2Cl_2 leads to a mixture of *R* and *S* products and thus to a lower enantioselectivity.^[22]

The use of PC would be especially beneficial if the separation of the expensive catalyst in a two-phase mixture were possible. The yellow iridium complex $[\text{Ir}(\text{cod})(\mathbf{4})]\text{BAR}^{\text{F}}_4$ (Figure 1) is located exclusively in the PC phase.



Figure 1. Two-phase system composed of *n*-hexane and PC with $[\text{Ir}(\text{cod})(\mathbf{4})]\text{BAR}^{\text{F}}_4$.

In a typical experiment olefin **5** was hydrogenated in PC and the product was removed by extraction with *n*-hexane. The catalyst can be used up to five times without significant loss in enantioselectivity or an increase in the formation of isomer **6** (Table 5), although an increase in reaction time was

Table 5: Recycling experiments with the catalyst $[\text{Ir}(\text{cod})(\mathbf{4})]\text{BAR}^{\text{F}}_4$ and olefin **5** as substrate in PC.^[a]

Cycle ^[b]	<i>t</i> [h]	Conv. [%]	6/7 ^[c]	<i>ee</i> [%]
1	4	100	1.5:98.5	83.1 (<i>R</i>)
2	6	100	3:97	84.6 (<i>R</i>)
3	20	100	2:98	83.7 (<i>R</i>)
4	20	100	1.5:98.5	83.4 (<i>R</i>)
5	20	100	1.5:98.5	83.4 (<i>R</i>)
6	20	100	2:98	79.2 (<i>R</i>)
7	20	85	4.5:95.5	58.8 (<i>R</i>)
8	20	63	5:95	50.5 (<i>R</i>)

[a] Conditions: 0.4 mmol substrate, 0.004 mmol $[\text{Ir}(\text{cod})(\mathbf{4})]\text{BAR}^{\text{F}}_4$, $p(\text{H}_2) = 85$ bar, 2 mL LM, 25 °C. [b] The catalyst was reused after liquid–liquid extraction with *n*-hexane. [c] Determined by NMR spectroscopy and GC on chiral phase.

observed. The iridium complex probably passes in part into the hexane phase, which could explain the loss in reactivity on repeated use. Modification of the ligand to improve catalyst solubility in PC could be of help.

The results illustrate the considerable potential of PC in asymmetric hydrogenation. In the reaction of functionalized olefins, the results obtained are similar to or better than those

obtained in standard solvents. The asymmetric hydrogenation of nonfunctionalized olefins appears particularly interesting, since then a nonpolar product is formed which can be removed by extraction and the catalyst can be used repeatedly. Further asymmetric catalysis in PC and other organic carbonates is currently under investigation.

Received: March 6, 2007

Published online: July 3, 2007

Keywords: asymmetric catalysis · green chemistry · hydrogenations · iridium · solvent effects

- [1] a) *Chemistry in Alternative Reaction Media*, Wiley, Chichester, 2004; b) *Multiphase Homogeneous Catalysis* (Eds.: B. Cornils, W. A. Herrmann, I. T. Horvath, W. Leitner, S. Mecking, H. Olivier-Bourbigou, D. Vogt), Wiley-VCH, Weinheim, 2005.
- [2] *Aqueous-Phase Organometallic Catalysis* (Eds.: B. Cornils, W. A. Herrmann), Wiley-VCH, 1998.
- [3] “Fluorous Catalyst”: I. Horvath in *Multiphase Homogeneous Catalysis* (Eds.: B. Cornils, W. A. Herrmann, I. T. Horvath, W. Leitner, S. Mecking, H. Olivier-Bourbigou, D. Vogt), Wiley-VCH, Weinheim, 2005, p. 339–404.
- [4] “Catalysis Using Supercritical Solvents”: W. Leitner, A. M. Scurto, C. M. Gordon, P. G. Jessop, D. J. Cole-Hamilton, T. Kunene, P. B. Webb, K. Burgemeister, M. Poliakoff in *Multiphase Homogeneous Catalysis* (Eds.: B. Cornils, W. A. Herrmann, I. T. Horvath, W. Leitner, S. Mecking, H. Olivier-Bourbigou, D. Vogt), Wiley-VCH, Weinheim, 2005, p. 605–750.
- [5] *Ionic Liquids in Synthesis* (Eds.: P. Wasserscheid, T. Welton), Wiley-VCH, Weinheim, 2003.
- [6] a) A. Behr, F. Naendrup, D. Obst, *Eur. J. Lipid Sci. Technol.* 2002, 104, 161–166; b) A. Behr, N. Tosly, *Chem. Eng. Technol.* 2000, 23, 122–125; c) A. Behr, F. Naendrup, D. Obst, *Adv. Synth. Catal.* 2002, 344, 1142–1145.
- [7] a) A. Behr, D. Obst, C. Schulte, T. Schosser, *J. Mol. Catal. A* 2003, 197, 115–126; b) A. Behr, D. Obst, B. Turkowski, *J. Mol. Catal. A* 2005, 226, 215–219.
- [8] M. T. Reetz, G. Lohner, *Chem. Commun.* 1996, 1921–1922.
- [9] Selected properties of PC: m.p. –48 °C; b.p. 242 °C; vapor pressure: 0.045 mm Hg at 25 °C; solubility in water: 175.00 mg L^{–1} at 25 °C; stable in water at pH 4, decomposition begins at higher pH values and at higher temperatures; UV stable; totally biodegradable; LC₅₀ = 480 mg L^{–1} (fish, butylene carbonate); EC₅₀ = > 5000 mg kg^{–1} (invertebrates); EC₅₀ = > 929 mg kg^{–1} (aquatic plants); EC₅₀ = > 5000 mg kg^{–1} (acute toxicity, oral); EC₅₀ = > 3000 mg kg^{–1} (acute toxicity, dermal); no gentotoxicity; repeated administration to rats (male/female): > 5000 mg kg^{–1} (oral); repeated administration to rats (male/female): > 100 mg m^{–3} (inhalation).
- [10] BASF recently presented a study in which PC and cresol were compared as solvents in the covering of copper wire from both economic and ecological standpoints. For most of the properties investigated PC was clearly superior. <http://www.corporate.basf.com/en/sustainability>.
- [11] For example, the Huntsman Corporation produces roughly 32000 t alkyl carbonates per annum by ring-opening of the respective epoxide. <http://www.huntsman.com>.
- [12] J. Holz, O. Zayas, H. Jiao, W. Baumann, A. Spannenberg, A. Monsees, T. H. Riermeier, J. Almendra, R. Kadyrov, A. Börner, *Chem. Eur. J.* 2006, 12, 5001–5013.
- [13] M. J. Burk, *J. Am. Chem. Soc.* 1991, 113, 8518–8519.
- [14] A. Miyashita, A. Yasuda, H. Takaya, K. Toriumi, T. Ito, T. Souchi, R. Noyori, *J. Am. Chem. Soc.* 1980, 102, 7932–7934.

- [15] K. Mashima, K. Kusano, N. Sato, Y. Matsumura, K. Nozaki, H. Kumobayashi, N. Sayo, Y. Hori, T. Ishizaki, S. Akutagawa, H. Takaya, *J. Org. Chem.* **1994**, *59*, 3064–3075.
- [16] A. Togni, C. Breutel, A. Schnyder, F. Spindler, H. Landert, A. Tijani, *J. Am. Chem. Soc.* **1994**, *116*, 4062–4066.
- [17] Comparative measurements on the hydrogenation of cyclo-octadiene- and norbornadiene-rhodium complexes provided first indications that the catalytically active complex was formed at about the same rate in PC as in other solvents; “Catalyst Inhibition and Deactivation in Homogeneous Hydrogenation”: D. Heller, A. H. M. de Vries, J. G. de Vries in *Handbook of Homogeneous Hydrogenation* (Eds.: J. G. de Vries, C. J. Elsevier), Wiley-VCH, Weinheim, **2007**, chap. 44.
- [18] a) S. Nanchen, A. Pfaltz, *Chem. Eur. J.* **2006**, *12*, 4550–4558; b) C. Hedberg, K. Kallstrom, P. Brandt, L. K. Hansen, P. G. Andersson, *J. Am. Chem. Soc.* **2006**, *128*, 2995–3001; c) X. Cui, K. Burgess, *Chem. Rev.* **2005**, *105*, 3272–3296; d) S. P. Smidt, F. Menges, A. Pfaltz, *Org. Lett.* **2004**, *6*, 2023–2026; e) A. Lightfoot, P. Schnider, A. Pfaltz, *Angew. Chem.* **1998**, *110*, 3047–3050; *Angew. Chem. Int. Ed.* **1998**, *37*, 2897–2899.
- [19] a) F. Menges, A. Pfaltz, *Adv. Synth. Catal.* **2002**, *344*, 40–44; b) S. McIntyre, E. Hörmann, F. Menges, S. P. Smidt, A. Pfaltz, *Adv. Synth. Catal.* **2005**, *347*, 2–3, 282–288.
- [20] S. Verevkin, B. Schäffner, V. Andrushko, A. Börner, unpublished results.
- [21] To study the isomerization, samples of the substrate were stirred under argon in the presence of the prehydrogenated precatalyst and then analyzed: PC: 39% (10 min), 83% (1 h); CH₂Cl₂: 100% (10 min).
- [22] Comparable isomerizations have been observed previously in the ruthenium-catalyzed hydrogenation of geraniol: a) Y. Sun, C. LeBlond, J. Wang, D. G. Blackmond, *J. Am. Chem. Soc.* **1995**, *117*, 12647–12648; b) Y. Sun, J. Wang, C. LeBlond, R. N. Landau, J. Laquidona, J. R. Sowa Jr, D. G. Blackmond, *J. Mol. Catal. A* **1997**, *115*, 495–502.